• 1-800-322-0808
  • drugsdepot@yahoo.com
  • Site Map

   

Valley Medical Pharmacy
630 Main Street (Store: 9am to 5.45pm)
Brawley, CA 92227  eRx ID#0585957
1 (800) 322-0808  Toll Free Fax: 1 (855) 322-0808 


Menu

Dilantin Inft 50 Mg Chewable 100 By Pfizer Pharma

Image 0 of Dilantin Inft 50 Mg Chewable 100 By Pfizer PharmaImage 1 of Dilantin Inft 50 Mg Chewable 100 By Pfizer Pharma

Dilantin Inft 50 Mg Chewable 100 By Pfizer Pharma

CALL US FOR THE PRICE

Dilantin Inft 50 Mg Chewable 100 By Pfizer Pharma. This Item Requires A Valid Order From A Physician Licensed in USA. Item Number.:RXD1070051/RXB10008345/RXA310022
Size : 100
Selling UoM : EA
NDC: 00071-0007-24
UPC Barcode : 300710007246
Supplier: 0050000308 PFIZER PHARM
Supplier Material : 7608
Generic Code : 004531 PHENYTOIN ORAL TAB CHEW 50 MG
Fine Line Class : 850085008510 All Rx Products
Product Category : RX Pharmaceuticals
Product Type : BRX Branded RX

Have a question?

  Please call or email to order

Product Description.:

P-D 007
chewable tablet , yellow , scored , triangular 3 sided

Phenytoin sodium is an antiepileptic drug. Phenytoin sodium is related to the barbiturates in chemical structure, but has a five-membered ring.

Each Dilantin? 100 mg Extended Oral Capsule?contains 100 mg phenytoin sodium. Also contains lactose monohydrate, NF confectioner's sugar, NF talc, USP and magnesium stearate, NF. The capsule body contains titanium dioxide, USP and gelatin, NF. The capsule cap contains FD&C red No. 28 FD&C yellow No. 6 and gelatin NF. Product in vivo performance is characterized by a slow and extended rate of absorption with peak blood concentrations expected in 4 to 12 hours as contrasted to Prompt Phenytoin Sodium Capsules, USP with a rapid rate of absorption with peak blood concentration expected in 1% to 3 hours.

click here for prescribing information

INDICATIONS
Dilantin is indicated for the control of generalized tonic-clonic (grand mal) and complex partial (psychomotor, temporal lobe) seizures and prevention and treatment of seizures occurring during or following neurosurgery.

Phenytoin serum level determinations may be necessary for optimal dosage adjustments

SIDE EFFECTS

Central Nervous System: The most common manifestations encountered with phenytoin therapy are referable to this system and are usually dose-related. These include nystagmus, ataxia, slurred speech, decreased coordination, and mental confusion. Dizziness, insomnia, transient nervousness, motor twitchings, and headaches have also been observed. There have also been rare reports of phenytoin-induced dyskinesias, including chorea, dystonia, tremor, and asterixis, similar to those induced by phenothiazine and other neuroleptic drugs.

A predominantly sensory peripheral polyneuropathy has been observed in patients receiving long-term phenytoin therapy.

Gastrointestinal System: Nausea, vomiting, constipation, toxic hepatitis, and liver damage.

Integumentary System: Dermatological manifestations sometimes accompanied by fever have included scarlatiniform or morbilliform rashes. A morbilliform rash (measles-like) is the most common other types of dermatitis are seen more rarely. Other more serious forms which may be fatal have included bullous, exfoliative or purpuric dermatitis, lupus erythematosus, Stevens-Johnson syndrome, and toxic epidermal necrolysis (see PRECAUTIONS section).

Hemopoietic System: Hemopoietic complications, some fatal, have occasionally been reported in association with administration of phenytoin. These have included thrombocytopenia, leukopenia, granulocytopenia, agranulocytosis, and pancytopenia with or without bone marrow suppression. While macrocytosis and megaloblastic anemia have occurred, these conditions usually respond to folic acid therapy. Lymphadenopathy including benign lymph node hyperplasia, pseudolymphoma, lymphoma, and Hodgkin's disease have been reported (see WARNINGS section).

Connective Tissue System: Coarsening of the facial features, enlargement of the lips, gingival hyperplasia, hypertrichosis, and Peyronie's disease.

Immunologic: Hypersensitivity syndrome (which may include, but is not limited to, symptoms such as arthralgias, eosinophilia, fever, liver dysfunction, lymphadenopathy, or rash), systemic lupus erythematosus, periarteritis nodosa and immunoglobulin abnormalities.